Penumbra (PEN) shares are in focus after the company reported positive 3 month outcomes from its STORM-PE trial, where computer assisted vacuum thrombectomy plus anticoagulation outperformed anticoagulation alone in pulmonary embolism patients.

The latest clinical data arrives after a mixed stretch for the stock, with a 90 day share price return of an 8.21% decline but a year to date share price return of 6.62%. Meanwhile, the 1 year total shareholder return of 10.95% and 5 year total shareholder return of 10.66% suggest steadier gains over time.

If this kind of healthcare technology story is on your radar, it can be useful to compare it with other specialist names and scan a wider field of healthcare related AI opportunities using the 33 healthcare AI stocks

So with Penumbra trading at US$329.89, a 10.9% 1 year total return, and clinical data backing its CAVT platform, are you looking at an underappreciated growth story, or has the market already priced in what comes next?

Most Popular Narrative: 9.8% Undervalued

The most followed narrative for Penumbra pegs fair value at $365.79 per share, slightly above the last close at $329.89, and builds a case around clinical data, product launches, and global expansion.

The soon-to-be-released STORM-PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism; a positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Curious what earnings profile and margin path sit behind that fair value, and why the implied future P/E multiple stays well above the industry? The full narrative sets out a specific revenue ramp, profitability shift, and valuation bridge that explain how analysts get from today’s numbers to that $365.79 figure.

Result: Fair Value of $365.79 (UNDERVALUED)

However, this story can change quickly if fresh trial data disappoints or if rising competition in thrombectomy and embolization starts to squeeze Penumbra’s margins.

Another Way To Look At Valuation

The popular fair value story suggests Penumbra is 9.8% undervalued at $329.89. However, the current 73x P/E is well above the US Medical Equipment industry at 25.1x, peers at 32.6x, and the 28.2x fair ratio that the market could move toward.

That kind of gap can work in your favor if earnings and sentiment continue to support a premium. It also means there is less room for error if growth, margins, or clinical momentum slip from current expectations.

Next Steps

With sentiment split between premium valuation and clinical momentum, it helps to move fast and check the underlying data for yourself. You can start with the 2 key rewards.

Looking for more investment ideas?

If you stop with a single stock, you miss the bigger picture across sectors and styles, so broaden your watchlist and let fresh ideas come to you.

• Spot potential value opportunities early by scanning companies that screen as high quality and potentially mispriced using the 54 high quality undervalued stocks.
• Strengthen your focus on resilience by filtering for businesses with robust finances through the solid balance sheet and fundamentals stocks screener (42 results).
• Hunt for underfollowed opportunities by reviewing the screener containing 25 high quality undiscovered gems that combine solid fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.